ReviewWorld journal of hepatology2015
Treating morbid obesity in cirrhosis: A quest of holy grail.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Challenges and strategies for optimizing liver transplantation outcomes in morbidly obese cirrhotic patients: a narrative review.BMC surgery · 2025Review
- Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease.International journal of molecular sciences · 2023Review
- Management and Risks Before, During, and After Liver Transplant in Individuals With Obesity.Gastroenterology & hepatology · 2023Article
- Is Fasting Good When One Is at Risk of Liver Cancer?Cancers · 2022Review
- A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.Translational gastroenterology and hepatology · 2022Review
- Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact.International journal of molecular sciences · 2021Review
- Outcomes of Bariatric Surgery in Chronic Liver Disease: a National Inpatient Sample Analysis.Obesity surgery · 2020Article
- Obesity in the Liver Transplant Setting.Nutrients · 2019Review
- Sarcopenia in the Cirrhotic Patient: Current Knowledge and Future Directions.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The problem of obesity is increasing worldwide in epidemic proportions; the situation is similarly becoming more common in patients with cirrhosis which negatively affect the prognosis of disease and also makes liver transplantation difficult especially in the living donor liver transplantation setting where low graft to recipient weight ratio negatively affects survival. Treatment of obesity is difficult in cirrhosis due to difficulty in implementation of lifestyle measures, limited data on safety of anti-obesity drugs and high risk of surgery. Currently approved anti-obesity drugs have limited data in patients with cirrhosis. Bariatric surgery remains an option in selected compensated cirrhotic patients. Endoscopic interventions for obesity are emerging and are quite promising in patients with cirrhosis as these are minimally invasive. In present review, we briefly discuss various modalities of weight reduction in obese patients and their applicability in patients with cirrhosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.